Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s assets in a transaction valued at up to $125 million. The deal is structured as an upfront payment of $57.5 million followed by up to an additional $67.5 million in conditional milestone payments. Teva will be the party that establishes the initial baseline bid in a court-supervised Section 363 auction process under US bankruptcy law, allowing other buyers to compete for the assets before the sale is completed.
Rapid Bankruptcy
On August 27, BioXcel Therapeutics, Inc. filed for Chapter 11 bankruptcy protection, following a weeks-long cash crisis. The company had informed investors that it didn’t have enough money to fund operations beyond the end of August, and it had acquired an emergency loan earlier in the week before filing for bankruptcy, citing a lack of a sustainable solution to its financial troubles. To continue operating during the court process, BioXcel secured $19 million in debtor-in-possession funding from current lenders. Following the bankruptcy filing, BioXcel Therapeutics, Inc. shares dropped by more than 70% to roughly $0.19.
What Teva Is Buying
The deal focuses on BioXcel’s neuroscience portfolio, which includes two related assets. The first is Igalmi, a dexmedetomidine sublingual film that is already approved and commercially available as a treatment for acute agitation related to schizophrenia or bipolar I or II disorder in adults. BioXcel Therapeutics, Inc. has stated that Igalmi will remain commercially available to patients during the bankruptcy process. The second is the pending label expansion for BXCL501, the dexmedetomidine sublingual film marketed as Igalmi for its currently approved indication. The FDA is reviewing an sNDA for potential at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, with a PDUFA target action date of November 14.
Part of a Broader Neuroscience Push
Teva Pharmaceutical Industries Limited has been steadily rebuilding its neuroscience portfolio as part of what the company calls its “Pivot to Growth” strategy, and business development executive vice president Evan Lippman linked the deal to that effort, stating that business development is critical to boosting the strategy and that the BioXcel Therapeutics, Inc. assets reflect a planned approach to seeking out innovative products with clear strategic fit and long-term growth potential. This isn’t Teva’s only recent neuroscience acquisition either. Back in April, the company signed a separate formal agreement to acquire Emalex Biosciences, including its lead asset, ecopipam, for $700 million. The transaction was completed in June.
Hedge Fund Sentiment
Hedge fund ownership of Teva Pharmaceutical Industries Limited increased modestly, from 52 in the first quarter to 54 in the second. Meanwhile, given its financial problems, BioXcel Therapeutics, Inc. received limited and diminishing institutional interest, with hedge fund holdings falling from 4 to 3 funds over the same period.
The Bull Case
The case for Teva Pharmaceutical Industries Limited is based on acquiring a commercially accessible, already-approved medication in Igalmi at a low upfront cost, with the pending BXCL501 outpatient expansion giving significant additional upside if the FDA aproves the expanded indication around the November 14 PDUFA target date. The deal’s structure, which includes a hefty conditional milestone component, reduces Teva’s downside risk if the expanded indication doesn’t pan out as expected, while also providing exposure to the upside. The acquisition also fits neatly with Teva’s claimed “Pivot to Growth” neuroscience strategy, complementing the separate $700 million Emalex Biosciences transaction and implying a deliberate effort to develop a specific therapeutic area rather than fragmented, opportunistic deal-making.
The Bear Case
However, since this is a Section 363 auction, Teva’s offer is simply a starting point, and other bidders could come up and raise the final price before the sale ends. Despite possessing an approved, commercially available medicine in Igalmi, BioXcel’s financial collapse raises questions about how much actual commercial momentum that product had prior to bankruptcy, raising questions about Igalmi’s commercial traction and whether its sales were sufficient to support BioXcel’s broader cost structure. The pending FDA decision on BXCL501’s outpatient expansion, which is due on November 14, adds another regulatory risk to the deal’s value, and if rejected, Teva will have a smaller, less distinctive asset than the acquisition currently suggests.
Insider Monkey’s Bottom Line
Given the low upfront cost and milestone-weighted structure, the deal limits Teva’s upfront financial exposure and it fits well into the company’s broader neuroscience buildout alongside the Emalex transaction. Investors should closely monitor the Section 363 auction process, as a competing bid could change the deal’s economics before it is finalized, and should view the FDA’s November 14 decision on BXCL501 as a key catalyst in determining whether this acquisition delivers the growth potential Teva claims. For BioXcel Therapeutics, Inc., this move is expected to mark the company’s practical end as an independent entity, with the outcome for existing shareholders heavily influenced by how the bankruptcy court auction and subsequent creditor claims are addressed.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
